<DOC>
	<DOCNO>NCT01687244</DOCNO>
	<brief_summary>This Phase 2 study design ass efficacy safety INSTILADRIN ( rAd-IFN Syn3 ) give intravesically patient high grade non-muscle invasive bladder cancer refractory relapse BCG therapy . The pharmacodynamics INSTILADRIN also study measure interferon ( IFNα2b ) level excrete urine . rAd-IFN non-replicating recombinant adenovirus type 5 ( Ad5 ) -vector encode interferon alpha-2b ( IFNα2b ) gene . Syn 3 clinical surfactant excipient enhances ability adenoviral vector transfect cell bladder wall .</brief_summary>
	<brief_title>Intravesical Administration rAd-IFN/Syn3 Patients With BCG-Refractory Relapsed Bladder Cancer</brief_title>
	<detailed_description>Criteria Evaluation : Efficacy : A Response define evidence recurrence high grade tumor cystoscopy , cytology clinically indicate , biopsy . Safety : The safety tolerability INSTILADRIN evaluate base adverse event report , vital sign , ECGs , clinical laboratory value result physical examination .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>1 . Aged 18 year old time consent 2 . Able give inform consent 3 . Subjects high grade BCGrefractory relapse NMIBC include High grade noninvasive papillary carcinoma ( Ta ) subject high grade tumor invade subepithelial connective tissue ( T1 ) Carcinoma situ ( CIS ) CIS Ta T1 tumor Refractory define failure achieve diseasefree state six month adequate induction BCG therapy either maintenance reinduction 3 month . Adequate induction define minimum 5 6 induction dos adequate maintenance define minimum 2 3 dos treatment . Relapse define recurrence within 1 year complete response BCG treatment 4 . Complete resection visible papillary lesion CIS TURBT endoscopic resection 14 60 day prior begin study treatment 5 . Available whole duration study 6 . Life expectancy &gt; 2 year , opinion investigator 7 . ECOG status 2 less 8 . Absence upper tract urothelial carcinoma 9 . Female subject childbearing potential must use maximally effective birth control period therapy , must willing use contraception 1 month follow last study drug infusion must negative urine serum pregnancy test upon entry study . Otherwise , female subject must postmenopausal ( menstrual period minimum 12 month ) surgically sterile . 10 . Male subject must surgically sterile willing use double barrier contraception method upon enrollment , course study , 1 month follow last study drug infusion . 11 . Adequate laboratory value . Hemoglobin ≥10 g/dL . WBC ≥4000/μL . ANC ≥2000/μL . Platelet count ≥100,000/μL . INR within institutional normal limit . aPTT within institutional normal limit . AST ≤1.5 x ULN . ALT ≤1.5 x ULN . Total bilirubin within institutional normal limit . Creatinine ≤1.5 x ULN . 1 . Current previous evidence muscle invasive metastatic disease 2 . Current systemic therapy bladder cancer 3 . Current prior pelvic external beam radiotherapy 4 . Prior treatment adenovirusbased drug 5 . Suspected hypersensitivity interferon alpha 6 . Existing urinary tract infection bacterial cystitis 7 . Clinically significant unexplained elevate liver renal function test 8 . Women pregnant lactate 9 . Severe cardiovascular disease 10 . History malignancy organ system within past 5 year ( except treat basal cell carcinoma squamous cell carcinoma skin ) 11 . Subjects hold instillation 1 hour 12 . Subjects tolerate intravesical dose intravesical surgical manipulation 13 . Intravesical therapy within 6 week enrollment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>BCG Refractory Relapsed Superficial Bladder Cancer</keyword>
	<keyword>rAd-IFN</keyword>
	<keyword>Syn3</keyword>
	<keyword>Intravesical</keyword>
	<keyword>transitional cell carcinoma bladder</keyword>
	<keyword>superficial non-muscle invasive tumor</keyword>
	<keyword>Interferon alpha2b</keyword>
	<keyword>INSTILADRIN</keyword>
</DOC>